SCHEMBL21747546

SCHEMBL21747546

O=C(NCc1ccc(F)cc1)Oc1nc(-c2cc(F)ncc2Cl)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 3/20 0.41
▸ CDK9 P50750 3/20 0.41
▸ FAAH O00519 2/20 0.40
▸ EIF4E P06730 1/20 0.40
▸ ROCK2 O75116 1/20 0.39
▸ ROCK1 Q13464 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PTGER4 P35408 1/20 0.37
▸ PTGER2 P43116 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ CCNT1 O60563 1/20 0.36
▸ CNR1 P21554 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21747560 0.81 CCNK (0.54) CCNKCDK9CCNT1
SCHEMBL21747522 0.81 CCNK (0.43) CCNKCDK9SMN1; SMN2ALDH1A1MAPT
SCHEMBL21747543 0.79 CCNK (0.52) CCNKCDK9CCNT1
SCHEMBL21747572 0.78 CCNK (0.43) CCNKCDK9EIF4EGAAMAPT
SCHEMBL21747535 0.77 CDK9 (0.65) CCNKCDK9EIF4ECCNT1
SCHEMBL21747513 0.74 CDK9 (0.46) CCNKCDK9CCNT1
SCHEMBL23125463 0.69 GRM2 (0.39) CCNKCDK9MEN1KMT2ACCNT1
SCHEMBL21747517 0.67 CCNK (0.54) CCNKCDK9KMT2ASMN1; SMN2MAPT
SCHEMBL23125453 0.66 PKM (0.52) CCNKCDK9SMN1; SMN2MAPT
SCHEMBL21747554 0.64 CCNK (0.66) CCNKCDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3613737-B1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2021-12-29 — — EP disclosed
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2021-03-23 — — US disclosed
US-20200078343-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) 2020-03-12 — — US disclosed
EP-3613737-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 Genfleet Therapeutics (Shanghai) Inc. (CN) 2020-02-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10952999-B2 Inhibitor of cyclin-dependent kinase CDK9 CDK9, CDK19, CDK1 CCNK 14/4885CDK9 1/4885FAAH 3502/4885
US-20200078343-A1 NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 CDK9, CDK19, CDKL1 CCNK 17/4885CDK9 1/4885FAAH 3663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback